Clinical trials: HIV -1 Infection
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
Study CP-MGD020-01 is a phase 1, open-label, dose-escalation, and multi-dose expansion study of MGD020 as a single agent or in combination with MGD014 in persons with HIV-1 (PWH) on antiretroviral therapy (ART).
- Conditions
- Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
- Trial name
- NCT05261191
- Testing
- MGD020, MGD014
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- MacroGenics
HIV Infections
A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
The purpose of this study is to see if it is safe and effective to give 1592U89 plus certain protease inhibitors (PIs) to HIV-infected patients who never have been treated with anti-HIV drugs.
- Trial name
- NCT00002440
- Testing
- Indinavir sulfate, Ritonavir, Abacavir sulfate
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Glaxo Wellcome
HIV Infections, HIV-1
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible…
- Trial name
- NCT00980538
- Testing
- Etravirine
- Where
- 29 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Janssen Sciences Ireland UC
HIV Infections
The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs
To compare the safety, tolerance, durability of the viral load response and the antiviral activity of the 1592U89/zidovudine(ZDV)/lamivudine (3TC) regimen vs. ZDV/3TC regimen.
- Trial name
- NCT00002391
- Testing
- Abacavir sulfate, Lamivudine, Zidovudine
- Where
- 30 sites in United States
- Sponsor
- Glaxo Wellcome
HIV-1
PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
The purpose of the study is to determine the safety, tolerability and plasma pharmacokinetics (pk) (i.e., the levels of TMC558445 circulating in your blood over time) of increasing single oral doses of TMC558445 and of multiple…
- Trial name
- NCT00838760
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
This study is a phase 1, dose finding, open-label study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT02658968
- Testing
- Betalutin
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- Nordic Nanovector
HIV Infections
Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors
The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination containing indinavir and ritonavir to HIV-positive patients who have failed previous treatment with protease inhibitors.
- Trial name
- NCT00002361
- Testing
- Indinavir sulfate, Ritonavir
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infection
Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)
The study will evaluate the safety, tolerability, pharmacokinetics, and antiretroviral activity of a single dose of ulonivirine in antiretroviral therapy (ART)-naive, HIV-1 infected participants.
- Trial name
- NCT02174159
- Testing
- Ulonivirine
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine).
- Trial name
- NCT00002240
- Testing
- Atazanavir, Nelfinavir mesylate, Stavudine
- Where
- 17 sites in United States, Canada
- Sponsor
- Bristol-Myers Squibb
HIV-1-infection
Study of GS-1219 in Participants With HIV-1
This study is part of a master study. The goal of master protocol (GSUS-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1…
- Trial name
- NCT07115368
- Testing
- GS-1219, BVY, Standard of Care
- Where
- 15 sites in United States
- Volunteers
- 4 people
- Sponsor
- Gilead Sciences
AIDS
Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons
This study is designed to determine whether administration of the GSK Biologicals HIV vaccine 732462 can lead to a reduction in viral load, and impact on the course of human immunodeficiency virus type 1 (HIV-1) infection.
- Trial name
- NCT01218113
- Testing
- GSK Biologicals HIV Vaccine 732462
- Where
- 42 sites in United States, France and 2 more
- Volunteers
- 191 people
- Sponsor
- GlaxoSmithKline
HIV Infections
The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
To compare the effects on CD4 counts and safety of MK-639 (indinavir, IDV) and AZT administered concomitantly to MK-639 alone and AZT alone in HIV-1 seropositive patients.
- Trial name
- NCT00002443
- Testing
- Indinavir sulfate, Zidovudine
- Volunteers
- 780 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1-Infection
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
The goal of this clinical study is to learn more about the experimental drugs lepetegravir and lenacapavir pacfosacil; to compare the combination of lepetegravir and lenacapavir pacfosacil with the current standard-of-care…
- Trial name
- WONDERS1 (NCT06544733)
- Testing
- Lepetegravir, Lenacapavir pacfosacil, Bictegravir/emtricitabine/tenofovir alafenamide
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 675 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)
This is a study to evaluate the safety, tolerability, pharmacokinetics, and antiretroviral activity of doravirine (MK-1439) as monotherapy in antiretroviral therapy (ART)-naïve, HIV-1-infected participants.
- Trial name
- NCT01466985
- Testing
- Doravirine
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infection
A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)
This study aimed to investigate the influence of hepatic insufficiency on the pharmacokinetics (PK) of doravirine (MK-1439). In Part 1, PK of doravirine in participants with moderate hepatic insufficiency was compared with that…
- Trial name
- NCT02089659
- Testing
- Doravirine
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus-1 (HIV-1) Infection
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects
This is a randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single ascending dose (Part A) and multiple ascending dose (Part B) of HRS5685 tablet in healthy…
- Trial name
- NCT05328583
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- RetroLead (Shanghai) BioPharma Co., Ltd.
HIV-1, HIV Infections
A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents
The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time), safety, tolerability and antiviral activity to support dose recommendations of TMC114…
- Trial name
- NCT00355524
- Testing
- TMC114, Ritonavir
- Where
- 22 sites in United States, Argentina and 6 more
- Volunteers
- 80 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV-1-infection
External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA
Among heavily treatment experienced people living with HIV, the virologic effectiveness of ibalizumab + optimized background regimen from two clinical trials will be compared to non-ibalizumab-containing regimens in routine…
- Trial name
- NCT05495204
- Testing
- Ibalizumab
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Epividian
HIV-1 Infection
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
The purpose of the study was to evaluate the safety and efficacy of the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) compared with the efavirenz (EFV)/FTC/TDF STR in HIV-1…
- Trial name
- NCT01309243
- Testing
- FTC/RPV/TDF, EFV/FTC/TDF
- Where
- 151 sites in United States, Australia and 12 more
- Volunteers
- 799 people
- Sponsor
- Gilead Sciences
HIV-1/HBV Co-Infection
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults
The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate…
- Trial name
- Alliance (NCT03547908)
- Testing
- B/F/TAF, DTG, F/TDF
- Where
- 69 sites in United States, China and 12 more
- Volunteers
- 244 people
- Sponsor
- Gilead Sciences